Literature DB >> 16044311

Secondary Ph+ acute lymphoblastic leukemia after temozolomide.

Serena De Vita, Silvia De Matteis, Luca Laurenti, Patrizia Chiusolo, Giovanni Reddiconto, Alessia Fiorini, Giuseppe Leone, Simona Sica.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16044311     DOI： 10.1007/s00277-005-1093-6

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  11 in total

Review 1.  Metronomic chemotherapy: new rationale for new directions.

Authors:  Eddy Pasquier; Maria Kavallaris; Nicolas André
Journal:  Nat Rev Clin Oncol       Date:  2010-06-08       Impact factor: 66.675

2.  Acute lymphoblastic leukemia following temozolomide treatment in a patient with glioblastoma: A case report and review of the literature.

Authors:  Pengfei Liu; Peiwen Li; Ting Lei; Limei Qu; Haiyan Huang; Qingchun Mu
Journal:  Oncol Lett       Date:  2018-04-04       Impact factor: 2.967

Review 3.  Metronomic chemotherapy in progressive pediatric malignancies: old drugs in new package.

Authors:  Ankur Bahl; Sameer Bakhshi
Journal:  Indian J Pediatr       Date:  2012-04-28       Impact factor: 1.967

Review 4.  Targeting O⁶-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy.

Authors:  Bernd Kaina; Geoffrey P Margison; Markus Christmann
Journal:  Cell Mol Life Sci       Date:  2010-08-18       Impact factor: 9.261

5.  Acute lymphoblastic leukemia subsequent to temozolomide use in a 26-year-old man: a case report.

Authors:  Asim Jamal Shaikh; Nehal Masood
Journal:  J Med Case Rep       Date:  2010-08-18

Review 6.  Temozolomide-associated hypermutation in gliomas.

Authors:  Serah Choi; Yao Yu; Matthew R Grimmer; Michael Wahl; Susan M Chang; Joseph F Costello
Journal:  Neuro Oncol       Date:  2018-09-03       Impact factor: 12.300

7.  Configurational and Conformational Equilibria of N6-(2-Deoxy-d-erythro-pentofuranosyl)-2,6-diamino-3,4-dihydro-4-oxo-5- N-methylformamidopyrimidine (MeFapy-dG) Lesion in DNA.

Authors:  Stephanie N Bamberger; Chanchal K Malik; Markus W Voehler; Summer K Brown; Hope Pan; Tracy L Johnson-Salyard; Carmelo J Rizzo; Michael P Stone
Journal:  Chem Res Toxicol       Date:  2018-08-31       Impact factor: 3.739

8.  Secondary hematological malignancies associated with temozolomide in patients with glioma.

Authors:  Hiroyuki Momota; Yoshitaka Narita; Yasuji Miyakita; Soichiro Shibui
Journal:  Neuro Oncol       Date:  2013-03-21       Impact factor: 12.300

9.  Temozolomide in children with progressive low-grade glioma.

Authors:  Sridharan Gururangan; Michael J Fisher; Jeffrey C Allen; James E Herndon; Jennifer A Quinn; David A Reardon; James J Vredenburgh; Annick Desjardins; Peter C Phillips; Melody A Watral; Jeanne M Krauser; Allan H Friedman; Henry S Friedman
Journal:  Neuro Oncol       Date:  2007-03-08       Impact factor: 12.300

Review 10.  Metronomic chemotherapy.

Authors:  Rituparna Maiti
Journal:  J Pharmacol Pharmacother       Date:  2014-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.